Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).

Paolo Strati,Veronika Bachanova,Aaron M. Goodman,John M. Pagel,Januario E. Castro,Kelly Griffis,Marlisa Anderson,Siminder Kaur Atwal,Cara Bickers,Daniel Fremgen,Christina Ly,Sarah Cooley,Rebecca Elstrom,Krish Patel

Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).

2021

Paolo Strati
Veronika Bachanova
Aaron M. Goodman
John M. Pagel
Januario E. Castro
Kelly Griffis
Marlisa Anderson
Siminder Kaur Atwal
Cara Bickers
Daniel Fremgen
Christina Ly
Sarah Cooley
Rebecca Elstrom
Krish Patel

7541Background: FT516 is an investigational, NK cell cancer immunotherapy derived from a clonal master iPSC line. FT516 is engineered with a novel hnCD16 Fc receptor, demonstrated preclinically to ...

Keywords:

Induced pluripotent stem cell
Medicine
CD16
B-cell lymphoma
in patient
Cancer research
ipsc line
Fc receptor
Immunotherapy
Cell therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations